The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder

Overview

Journal Am J Psychiatry

Specialty Psychiatry

Date 2016 Oct 4

PMID 27690517

Citations 26

Authors

Alexander Viktorin

Eleonore Ryden

Michael E Thase

Zheng Chang

Cecilia Lundholm

Brian M DOnofrio

Catarina Almqvist

Patrik K E Magnusson

Paul Lichtenstein

Henrik Larsson

Mikael Landen

Affiliations

Soon will be listed here.

Abstract

Objective: The authors sought to determine the risk of treatment-emergent mania associated with methylphenidate, used in monotherapy or with a concomitant mood-stabilizing medication, in patients with bipolar disorder.

Method: Using linked Swedish national registries, the authors identified 2,307 adults with bipolar disorder who initiated therapy with methylphenidate between 2006 and 2014. The cohort was divided into two groups: those with and those without concomitant mood-stabilizing treatment. To adjust for individual-specific confounders, including disorder severity, genetic makeup, and early environmental factors, Cox regression analyses were used, conditioning on individual to compare the rate of mania (defined as hospitalization for mania or a new dispensation of stabilizing medication) 0-3 months and 3-6 months after medication start following nontreated periods.

Results: Patients on methylphenidate monotherapy displayed an increased rate of manic episodes within 3 months of medication initiation (hazard ratio=6.7, 95% CI=2.0-22.4), with similar results for the subsequent 3 months. By contrast, for patients taking mood stabilizers, the risk of mania was lower after starting methylphenidate (hazard ratio=0.6, 95% CI=0.4-0.9). Comparable results were observed when only hospitalizations for mania were counted.

Conclusions: No evidence was found for a positive association between methylphenidate and treatment-emergent mania among patients with bipolar disorder who were concomitantly receiving a mood-stabilizing medication. This is clinically important given that up to 20% of people with bipolar disorder suffer from comorbid ADHD. Given the markedly increased hazard ratio of mania following methylphenidate initiation in bipolar patients not taking mood stabilizers, careful assessment to rule out bipolar disorder is indicated before initiating monotherapy with psychostimulants.

Citing Articles

Mood Stabilizers for Treating Emotional Dysregulation in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) with or Without Comorbid Bipolar Spectrum Disorders.

Brancati G, De Rosa U, Magnesa A, De Dominicis F, Petrucci A, Schiavi E Brain Sci. 2025; 15(2).

PMID: 40002515 PMC: 11853101. DOI: 10.3390/brainsci15020182.

ADHD symptom trajectories across childhood and early adolescence and risk for hypomanic symptoms in young adulthood.

Durdurak B, Morales Munoz I, Morales-Munoz I, Hosang G, Marwaha S Eur Psychiatry. 2025; 68(1):e37.

PMID: 39967022 PMC: 11883789. DOI: 10.1192/j.eurpsy.2025.24.

Pediatric Bipolar Disorder: Challenges in Diagnosis and Treatment.

Wozniak J, OConnor H, Iorini M, Ambrose A Paediatr Drugs. 2024; 27(2):125-142.

PMID: 39592559 PMC: 11829910. DOI: 10.1007/s40272-024-00669-z.

The Emergence of Mania After Initiating Escitalopram for Anxiety Disorder.

Surineni K, Armstrong A, Wallace S, Schrader N Cureus. 2024; 16(6):e63441.

PMID: 39077268 PMC: 11284823. DOI: 10.7759/cureus.63441.

Compulsive Biting and Chewing with Mixed Amphetamine Salts: A Case Report.

Free M, Choi H, Baweja R Innov Clin Neurosci. 2024; 21(4-6):11-13.

PMID: 38938532 PMC: 11208004.

References

Scheffler R, Hinshaw S, Modrek S, Levine P . The global market for ADHD medications. Health Aff (Millwood). 2007; 26(2):450-7. DOI: 10.1377/hlthaff.26.2.450. View

Geddes J, Miklowitz D . Treatment of bipolar disorder. Lancet. 2013; 381(9878):1672-82. PMC: 3876031. DOI: 10.1016/S0140-6736(13)60857-0. View

Chang Z, Lichtenstein P, Halldner L, DOnofrio B, Serlachius E, Fazel S . Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014; 55(8):878-85. PMC: 4147667. DOI: 10.1111/jcpp.12164. View

McIntyre R, Alsuwaidan M, Soczynska J, Szpindel I, Bilkey T, Almagor D . The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol. 2013; 28(5):421-7. DOI: 10.1002/hup.2325. View

Tondo L, Vazquez G, Baldessarini R . Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2009; 121(6):404-14. DOI: 10.1111/j.1600-0447.2009.01514.x. View

Klassen L, Katzman M, Chokka P . Adult ADHD and its comorbidities, with a focus on bipolar disorder. J Affect Disord. 2009; 124(1-2):1-8. DOI: 10.1016/j.jad.2009.06.036. View

Scheffer R, Kowatch R, Carmody T, Rush A . Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2004; 162(1):58-64. DOI: 10.1176/appi.ajp.162.1.58. View

Fazel S, Zetterqvist J, Larsson H, Langstrom N, Lichtenstein P . Antipsychotics, mood stabilisers, and risk of violent crime. Lancet. 2014; 384(9949):1206-14. PMC: 4165625. DOI: 10.1016/S0140-6736(14)60379-2. View

Sellgren C, Landen M, Lichtenstein P, Hultman C, Langstrom N . Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden. Acta Psychiatr Scand. 2011; 124(6):447-53. DOI: 10.1111/j.1600-0447.2011.01747.x. View

10.

Pacchiarotti I, Bond D, Baldessarini R, Nolen W, Grunze H, Licht R . The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170(11):1249-62. PMC: 4091043. DOI: 10.1176/appi.ajp.2013.13020185. View

11.

Findling R, Short E, McNamara N, Demeter C, Stansbrey R, Gracious B . Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(11):1445-53. DOI: 10.1097/chi.0b013e31814b8d3b. View

12.

El-Mallakh R . An open study of methylphenidate in bipolar depression. Bipolar Disord. 2001; 2(1):56-9. DOI: 10.1034/j.1399-5618.2000.020108.x. View

13.

Thase M . Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol. 2006; 18(4):1213-30. DOI: 10.1017/S0954579406060585. View

14.

Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S . Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012; 367(21):2006-14. PMC: 3664186. DOI: 10.1056/NEJMoa1203241. View

15.

Ludvigsson J, Otterblad-Olausson P, Pettersson B, Ekbom A . The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659-67. PMC: 2773709. DOI: 10.1007/s10654-009-9350-y. View

16.

Perugi G, Vannucchi G . The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. Expert Opin Pharmacother. 2015; 16(14):2193-204. DOI: 10.1517/14656566.2015.1079620. View

17.

Polanczyk G, Silva de Lima M, Horta B, Biederman J, Rohde L . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007; 164(6):942-8. DOI: 10.1176/ajp.2007.164.6.942. View

18.

Viktorin A, Lichtenstein P, Thase M, Larsson H, Lundholm C, Magnusson P . The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014; 171(10):1067-73. DOI: 10.1176/appi.ajp.2014.13111501. View

19.

Larsson H, Ryden E, Boman M, Langstrom N, Lichtenstein P, Landen M . Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry. 2013; 203(2):103-6. PMC: 3730113. DOI: 10.1192/bjp.bp.112.120808. View

20.

Arnsten A . Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology. 2006; 31(11):2376-83. DOI: 10.1038/sj.npp.1301164. View